CliffBio
small molecule

RELEXXII

METHYLPHENIDATE HYDROCHLORIDE

Loss of exclusivityFebruary 2037latest FDA-listed patent expiry
CompanyOsmotica Pharmaceutical →See this company's full patent-cliff portfolio

Drug detail

Brand nameRELEXXII
Active ingredientMETHYLPHENIDATE HYDROCHLORIDE
Strength27MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalJune 2022
Marketing statusRX

Listed patents

PatentExpiresType
10695336February 2037use U-4032
10265308February 2037product
9855258February 2037product
9827234February 2037use U-4032
9707217February 2037product

More from Osmotica Pharmaceutical

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

RELEXXII patent cliff — loss of exclusivity February 2037 | CliffBio